TACE Plus Lenvatinib/Pembrolizumab Boosts PFS in Unresectable Liver Cancer
Adding lenvatinib/pembrolizumab to TACE elicits a numerical overall survival improvement in the LEAP-012 trial, although additional follow-up is necessary.
Related Articles
FDA Approves Acalabrutinib With Bendamustine and Rituximab for Frontline MCL | Blood Cancers Today
In the phase 3 ECHO trial, acalabrutinib with bendamustine and rituximab reduced the risk of disease progression or death by 27% compared with standard-of-care chemoimmunotherapy.
Evaluating a CNS-Penetrant EGFR Inhibitor in Brain Cancer
Liquid biopsy tests may help determine the extent of activity among patients who receive a novel fourth-generation EGFR inhibitor for brain cancer.
FDA Approves Datopotamab Deruxtecan for Advanced Breast Cancer
Datopotamab deruxtecan-dlnk received approval from the FDA for previously treated unresectable or metastatic, HR-positive, HER2-negative breast cancer.
New Tool Can Help Improve Health Equity in Cancer Centers : Oncology Times
An abstract is unavailable.
Distinctions Between Alteration Types, Therapeutic Classes Could Drive Optimal Treatment Selection in HER2-Mutant NSCLC
Nicolas Girard, MD, compares the predictive value, mechanisms of action, and safety or efficacy profile of HER2-targeted TKIs vs ADCs in NSCLC.
FDA approves datopotamab deruxtecan-dlnk for unresectable or metastati
On January 17, 2025, the Food and Drug Administration approved datopotamab deruxtecan-dlnk (Datroway, Daiichi Sankyo, Inc.), a Trop-2-directed antibody and topoisomerase inhibitor conjugate, for adult…
FDA Approves Dato-DXd in Metastatic HR+/HER2– Breast Cancer
Data from the TROPION-Breast01 trial support the FDA approval of datopotamab deruxtecan for those with metastatic HR–positive, HER2-negative breast cancer.
Program
Explore the program for the AACR Special Conference in Cancer Research: Acute Lymphoblastic Leukemia, held March 7-9, 2025, in San Diego.
FDA Approves Datopotamab Deruxtecan for Unresectable or Metastatic HR+/HER2-Negative Breast Cancer
The FDA approved datopotamab deruxtecan for select unresectable or metastatic, hormone receptor–positive, HER2-negative breast cancer.
A metabolic pathway for improving adoptive cellular therapy
In this issue of Cancer Cell, Qiu et al. use single-cell metabolic analysis to identify reduced mannose metabolism as a previously unknown feature of exhausted T cells.…
